Skip to main content

Advertisement

SpringerLink
Log in

Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Our objective was to assess the efficacy and toxicity of concurrent chemoradiotherapy with cisplatin + weekly divided-dose docetaxel in patients with stage III non-small-cell lung cancer (NSCLC).

Methods

A total of 34 patients aged less than 75 years old with locally advanced stage III NSCLC were enrolled. The patients received intravenous infusions of cisplatin (80 mg/m2; day 1) and docetaxel (20 mg/m2; days 1, 8, 15), followed by a week’s drug-free interval. Standard concurrent thoracic radiotherapy was given for 6 weeks (2 Gy per fraction; total dose, 60 Gy).

Results

Over Grade 3 neutropenia, esophagitis and pulmonary toxicities were observed in 23.5, 17.6 and 11.8% of the cases, respectively. One complete response and 20 partial responses were obtained, with an objective response rate of 61.8%. The median survival time was 26.4 months (95% CI 16.9—not reached) and the 1- and 3-year survival rates were 76.5 and 41.2%, respectively.

Conclusion

Cisplatin + weekly docetaxel with concurrent radiotherapy is a feasible and effective regimen for locally advanced NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Dillman RO, Herndon J, Seagren SL et al (1996) Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210–1215

    Article  PubMed  CAS  Google Scholar 

  2. Sause W, Kolesar P, Taylor SIV et al (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358–364

    Article  PubMed  CAS  Google Scholar 

  3. Belani CP, Choy H, Bonomi P et al (2005) Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23:5883–5891

    Article  PubMed  CAS  Google Scholar 

  4. Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692–2699

    PubMed  CAS  Google Scholar 

  5. Curran D, Scott C, Langer C et al (2003) Long-term benefit is observed in a phase III comparison of sequential versus concurrent chemo-radiotherapy for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 22:621

    Google Scholar 

  6. Fournel P, Robinet G, Thomas P et al (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95–01 Study. J Clin Oncol 23:5910–5917

    Article  PubMed  CAS  Google Scholar 

  7. Kunitoh H, Watanabe K, Furuse K et al (1996) Phase II trial of Decetaxel in previously untreated advanced non-small–cell lung cancer: a Japanese Cooperative study. J Clin Oncol 14:1649–1655

    PubMed  CAS  Google Scholar 

  8. Schiller JH, Harrington D, Belani CP et al (2002) Eastern Cooperative Oncology Group. For the Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

    Article  PubMed  CAS  Google Scholar 

  9. Kubota K, Watanabe K, Kunitoh H et al (2004) Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22:254–261

    Article  PubMed  CAS  Google Scholar 

  10. Choy H, Rodriguez S, Koester S et al (1993) Synergic effects of Taxol/Taxotere on radiation sensitivity on human tumor cell lines. Int J Radiat Oncol Biol Phys 24:274–275

    Google Scholar 

  11. Mason KA, Hunter NR, Milas M et al (1997) Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 3(12 Pt 1):2431–2438

    PubMed  CAS  Google Scholar 

  12. Karasawa K, Katsui K, Seki K et al (2003) Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer. Breast Cancer 10:268–274

    Article  PubMed  Google Scholar 

  13. Koukourakis MI, Kourousis C, Kamilaki M et al (1998) Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation. Eur J Cancer 34:838–844

    Article  PubMed  CAS  Google Scholar 

  14. Onishi H, Kuriyama K, Yamaguchi M et al (2003) Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no gut survival due to radiation pneumonitis. Lung Cancer 40:79–84

    Article  PubMed  Google Scholar 

  15. Koizumi T, Tsunoda T, Fujimoto K et al (2001) Phase I trial of weekly docetaxel combined with cisplatin in patients with non-small-cell lung cancer. Lung Cancer 34:125–131

    Article  PubMed  CAS  Google Scholar 

  16. Tsunoda T, Koizumi T, Hayasaka M et al (2004) Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 54:173–177

    Article  PubMed  CAS  Google Scholar 

  17. Alvarez MV, Cobreros G, Heras A et al (1978) Studies on cis-dichlorodiammineplatinum (II) as a radiosensitizer. Br J Cancer 3:68–72

    CAS  Google Scholar 

  18. Dewit L (1987) Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 13:403–426

    PubMed  CAS  Google Scholar 

  19. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655

    Article  PubMed  CAS  Google Scholar 

  20. National Cancer Institute: Common Toxicity Criteria (CTC) v 2.0. http://ctep.cancer.gov/reporting/ctc.html

  21. Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207–214

    Article  PubMed  CAS  Google Scholar 

  22. Yamamoto N, Nishimura Y, Nakagawa K et al (2006) Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer. Cancer Chemother Pharmacol 58:285–291

    Article  PubMed  CAS  Google Scholar 

  23. Wu HG, Bang YJ, Choi EK et al (2002) Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 52:75–80

    PubMed  CAS  Google Scholar 

  24. Mudad R, Ramsey M, Kovitz K et al (2003) Concomitant weekly docetaxel, cisplatin and radiotherapy in locally advanced non-small cell lung cancer: a dose finding study. Lung Cancer 39:173–177

    Article  PubMed  Google Scholar 

  25. Kiura K, Ueoka H, Segawa Y et al (2003) Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 89:795–802

    Article  PubMed  CAS  Google Scholar 

  26. Iwasaki Y, Ohsugi S, Natsuhara A et al (2006) Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer. Cancer Chemother Pharmacol 58:735–741

    Article  PubMed  CAS  Google Scholar 

  27. Albain KS, Crowley JJ, Turrisi AT 3rd et al (2002) A Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 20:3454–3460

    Article  PubMed  CAS  Google Scholar 

  28. Robert F, Spencer SA, Childs HA 3rd et al (2002) Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial. Lung Cancer 37:189–199

    Article  PubMed  Google Scholar 

  29. Hainsworth JD, Burris HA 3rd, Erland JB et al (1998) Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16:2164–2168

    PubMed  CAS  Google Scholar 

  30. Ohe Y, Niho S, Kakinuma R et al (2001) Phase I studies of cisplatin and docetaxel administration by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients. Jpn J Clin Oncol 31:100–106

    Article  PubMed  CAS  Google Scholar 

  31. Socinski MA, Zhang C, Herndon JE 2nd et al (2004) Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol 15:1033–1041

    Article  PubMed  CAS  Google Scholar 

  32. Hirose T, Mizutani Y, Ohmori T et al (2006) The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer. Cancer Chemother Pharmacol 58:361–367

    Article  PubMed  CAS  Google Scholar 

  33. Sakai H, Yoneda S, Kobayashi K et al (2004) Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer. Lung Cancer 43:195–201

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi Matsumoto, Nagano, 390-8621, Japan

    Masaru Nakamura, Tomonobu Koizumi, Munehara Hayasaka, Masanori Yasuo, Kenji Tsushima & Keishi Kubo

  2. Department of Radiology, Shinshu University School of Medicine, 3-1-1 Asahi Matsumoto, Nagano, 390-8621, Japan

    Kotaro Gomi & Naoto Shikama

Authors
  1. Masaru Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomonobu Koizumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Munehara Hayasaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masanori Yasuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenji Tsushima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Keishi Kubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kotaro Gomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Naoto Shikama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomonobu Koizumi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakamura, M., Koizumi, T., Hayasaka, M. et al. Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer. Cancer Chemother Pharmacol 63, 1091–1096 (2009). https://doi.org/10.1007/s00280-008-0837-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-008-0837-0

Keywords

Search

Navigation